Meridian Bioscience Inc (VIVO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Meridian Bioscience Inc stock (VIVO) is currently trading at $2.24. Meridian Bioscience Inc PE ratio is 35.39. Meridian Bioscience Inc PS ratio (Price-to-Sales) is 4.35. Analyst consensus price target for VIVO is $34.00. WallStSmart rates VIVO as Underperform.
- VIVO PE ratio analysis and historical PE chart
- VIVO PS ratio (Price-to-Sales) history and trend
- VIVO intrinsic value — DCF, Graham Number, EPV models
- VIVO stock price prediction 2025 2026 2027 2028 2029 2030
- VIVO fair value vs current price
- VIVO insider transactions and insider buying
- Is VIVO undervalued or overvalued?
- Meridian Bioscience Inc financial analysis — revenue, earnings, cash flow
- VIVO Piotroski F-Score and Altman Z-Score
- VIVO analyst price target and Smart Rating
Meridian Bioscience Inc
📊 No data available
Try selecting a different time range
Intrinsic Value Analysis for Value Investors
Insufficient data to calculate intrinsic value for VIVO.
Smart Analysis
Meridian Bioscience Inc (VIVO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, operating margin, institutional own.. Concerns around revenue growth and eps growth. Mixed signals suggest waiting for clearer direction before acting.
Meridian Bioscience Inc (VIVO) Key Strengths (3)
90.92% of shares held by major funds and institutions
Good growth relative to its price
Strong operational efficiency: $23 kept per $100 revenue
Meridian Bioscience Inc (VIVO) Areas to Watch (7)
Revenue declining -13.80%, a shrinking business
Earnings declining -13.00%, profits shrinking
Premium valuation at 4.4x annual revenue
Premium pricing at 3.9x book value
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Decent profitability, keeps $13 per $100 revenue
Supporting Valuation Data
Meridian Bioscience Inc (VIVO) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.7/10) while 7 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., PEG Ratio, Operating Margin. Valuation metrics including PEG Ratio (1.33) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 22.70%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Price/Sales. Some valuation metrics including Price/Sales (4.35), Price/Book (3.92) suggest expensive pricing. Growth concerns include Revenue Growth at -13.80%, EPS Growth at -13.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.20%, Profit Margin at 12.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -13.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Meridian Bioscience Inc (VIVO) · HEALTHCARE › PHARMACEUTICALS
The Big Picture
Meridian Bioscience Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 333M with 14% decline year-over-year. Profit margins of 12.8% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 1220.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Revenue contracted 14% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Meridian Bioscience Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor PHARMACEUTICALS industry trends, competitive moves, and regulatory changes that could impact Meridian Bioscience Inc.
Bottom Line
Meridian Bioscience Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 1:08:05 PM
About Meridian Bioscience Inc(VIVO)
NASDAQ
HEALTHCARE
PHARMACEUTICALS
USA
Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company is headquartered in Cincinnati, Ohio.